Sanofi's COVID-19 Vaccine Nuvaxovid Authorised In Canada
April 9 (Reuters) - Sanofi SA SASY.PA:
SANOFI BECOMES MARKET AUTHORIZATION HOLDER FOR NUVAXOVID® IN CANADA, EXPANDING COVID-19 VACCINE CHOICES FOR CANADIANS
TO MAKE NUVAXOVID AVAILABLE IN CANADA FOR FALL 2026-2027 SEASON
PROVINCIAL, TERRITORIAL AVAILABILITY TO BE CONFIRMED PENDING ONGOING DISCUSSIONS, ASSESSMENTS
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Musk’s XChat Is Coming to App Store, Meta, Apple and Finance World Are Trembling

Anthropic IPO 2026: What the Claude Mythos Release Delay Means for Investors and Stock Valuation

Microsoft Launches Its Own AI Models and Ditches OpenAI Dependence - Is MSFT Stock a Buy at $370?

Brent Spot $190 Warning: WTI Flips Global Benchmark in Rare Price Inversion as Geopolitical Tensions Flare

Intel Stock's Rare Surge: What’s Driving the Rally and Is It Worth Buying in 2026?

Tradingkey








